Tag Archives: Raju Prasad

William Blair Sticks to Its Buy Rating for Cellectis SA (CLLS)

William Blair analyst Raju Prasad maintained a Buy rating on Cellectis SA (CLLS – Research Report) today. The company’s shares closed last Monday at $17.03. According to TipRanks.com, Prasad is a 5-star analyst with an average return of 24.7% and

William Blair Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)

William Blair analyst Raju Prasad maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today. The company’s shares closed last Monday at $57.75. According to TipRanks.com, Prasad is a 5-star analyst with an average return of 23.4%

Selecta Biosciences (SELB) Initiated with a Buy at William Blair

Selecta Biosciences (SELB – Research Report) received a Buy rating from William Blair analyst Raju Prasad today. The company’s shares closed last Monday at $3.32, close to its 52-week high of $3.50. According to TipRanks.com, Prasad is a 5-star analyst

William Blair Sticks to Its Buy Rating for Alexion Pharmaceuticals (ALXN)

In a report released today, Raju Prasad from William Blair maintained a Buy rating on Alexion Pharmaceuticals (ALXN – Research Report). The company’s shares closed last Monday at $113.92. According to TipRanks.com, Prasad is a 5-star analyst with an average

William Blair Keeps Their Buy Rating on Cellectis SA (CLLS)

William Blair analyst Raju Prasad maintained a Buy rating on Cellectis SA (CLLS – Research Report) today. The company’s shares closed last Monday at $17.96. According to TipRanks.com, Prasad is a 5-star analyst with an average return of 23.7% and

William Blair Reaffirms Their Buy Rating on Alexion Pharmaceuticals (ALXN)

William Blair analyst Raju Prasad maintained a Buy rating on Alexion Pharmaceuticals (ALXN – Research Report) today. The company’s shares closed last Monday at $106.60. According to TipRanks.com, Prasad is a 5-star analyst with an average return of 23.4% and